The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled …
Background The low-grade chronic inflammation in diabetes plays an important role in
development of cardiovascular and renal complications. Sodium-glucose co-transporter-2 …
development of cardiovascular and renal complications. Sodium-glucose co-transporter-2 …
The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
P Bodnar, M Mazurkiewicz, T Chwalba, E Romuk… - Biomedicines, 2023 - mdpi.com
Heart failure (HF) is a multifactorial clinical syndrome involving many complex processes.
The causes may be related to abnormal heart structure and/or function. Changes in the renin …
The causes may be related to abnormal heart structure and/or function. Changes in the renin …
Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
X Li, Z Chen, X Sun, Y Yang, H Jin, N Liu - Acta Pharmacologica Sinica, 2024 - nature.com
Type 2 diabetes mellitus (T2DM) patients exhibit greater susceptibility to vascular
calcification (VC), which has a higher risk of death and disability. However, there is no …
calcification (VC), which has a higher risk of death and disability. However, there is no …
Clinical study of metabolic parameters, leptin and the SGLT2 inhibitor empagliflozin among patients with obesity and type 2 diabetes
Obesity is a major public health problem worldwide, and it is associated with many diseases
and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces …
and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces …
Doxorubicin‑induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways
A Malik, AK Bagchi, DS Jassal… - Molecular Medicine …, 2024 - spandidos-publications.com
Doxorubicin (Dox) exhibits a high efficacy in the treatment of numerous types of cancer.
However, the beneficial cytotoxic effects of Dox are often accompanied by an increase in the …
However, the beneficial cytotoxic effects of Dox are often accompanied by an increase in the …
Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes-the role …
Objective: Oxidative stress and hypoxia play an important role in the pathogenesis of various
cardiovascular diseases. We aimed to evaluate the effectiveness of sacubitril/valsartan (S/V) …
cardiovascular diseases. We aimed to evaluate the effectiveness of sacubitril/valsartan (S/V) …
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled …
R Laborante, G Savarese, G Patti… - European Heart …, 2024 - academic.oup.com
Although remarkable progress has been made in the management of acute coronary
syndromes (ACS), current rates of adverse cardiovascular events remain high, fuelling the …
syndromes (ACS), current rates of adverse cardiovascular events remain high, fuelling the …
SGLT2 inhibitors and diabetic kidney disease: targeting multiple and interrelated signaling pathways for renal protection
GS Papaetis - Current Molecular Pharmacology, 2024 - benthamdirect.com
Almost 20-40% of all patients suffering from diabetes mellitus experience chronic kidney
disease, which is related to higher mortality (cardiovascular and all-cause). The implication …
disease, which is related to higher mortality (cardiovascular and all-cause). The implication …
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
A Rastogi, JL Januzzi Jr - Journal of Clinical Medicine, 2023 - mdpi.com
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve
cardiovascular and renal outcomes in patients with established cardiovascular disease …
cardiovascular and renal outcomes in patients with established cardiovascular disease …
Empagliflozin reduces the adverse effects of diabetes mellitus on testicular tissue in type 2 diabetic Rats: A stereological and biochemical study
M Kiani, MS Mehranjani, MA Shariatzadeh - Biochemical Pharmacology, 2024 - Elsevier
Empagliflozin as an antioxidant decreases blood glucose and insulin resistance in type 2
diabetes mellitus. Base on the empagliflozin antioxidant properties we decided to …
diabetes mellitus. Base on the empagliflozin antioxidant properties we decided to …